Progressive Multifocal Leukoencephalopathy in Patients with Sarcoidosis
Neurol 82:1307-1313, Jamilloux, Y.,et al, 2014
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
JAMA Neurol 71:954-960, Clerico, M.,et al, 2014
Statin Use During Ischemic Stroke Hospitalization is Strongly Associated with Improved Poststroke Survival
Stroke 43:147-154, Flint, A.C.,et al, 2012
A 62-Year-Old Woman with Bizarre Behavior and Recurrent Episodes of Behavioral Arrest
Neurol 86:e62-e65, Briglia, H.,et al, 2016
Rebound Syndrome in Patients with Multiple Sclerosis after Cessation of Fingolimod Treatment
JAMA Neurol 73:790-794, Hatcher, S.E.,et al, 2016
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Histoplasmosis in Patient with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS)
Medicine 93:11-18, Myint, T.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Should Statins be Paused or Discontinued After Thrombolysis or Acute Intracerebral Hemorrhage? No!
Stroke 44:1472-1476, Scheitz, J.F.,et al, 2013
Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003